RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer

Lung Cancer

Volumn 83, Issue 1, 2014, Pages 23-29

  Fukatsu, Asuki ^a,b   Ishiguro, Futoshi ^a,b   Tanaka, Ichidai ^a,b   Kudo, Takumi ^c   Nakagawa, Kentaro ^c   Shinjo, Keiko ^a   Kondo, Yutaka ^a   Fujii, Makiko ^a   Hasegawa, Yoshinori ^b   Tomizawa, Kenji ^a   Mitsudomi, Tetsuya ^a,d   Osada, Hirotaka ^a,b   Hata, Yutaka ^c   Sekido, Yoshitaka ^a,b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

EGFR; Lymph node metastasis; Non small cell lung cancer; Pleural invasion; RASSF3; Tumor suppressor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; RAS PROTEIN; RASSF3 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER PATIENT; CELL ASSAY; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PLEURA METASTASIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WILD TYPE;

EGFR; LYMPH NODE METASTASIS; NON-SMALL CELL LUNG CANCER; PLEURAL INVASION; RASSF3; TUMOR SUPPRESSOR;

APOPTOSIS; CARCINOGENESIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; CELLS, CULTURED; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MONOMERIC GTP-BINDING PROTEINS; NEOPLASM STAGING; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84891736050     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.10.014     Document Type: Article

References (30)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Richter A.M., Pfeifer G.P., Dammann R.H. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009, 1796:114-128.
3. Pfeifer G.P., Dammann R., Tommasi S. RASSF proteins. Curr Biol 2010, 20:R344-R345.
4. Sherwood V., Recino A., Jeffries A., Ward A., Chalmers A.D. The N-terminal RASSF family: a new group of Ras-association-domain-containing proteins, with emerging links to cancer formation. Biochem J 2010, 425:303-311.
5. Underhill-Day N., Hill V., Latif F. N-terminal RASSF family: RASSF7-RASSF10. Epigenetics 2011, 6:284-292.
6. Dammann R., Li C., Yoon J.H., Chin P.L., Bates S., Pfeifer G.P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000, 25:315-319.
7. Burbee D.G., Forgacs E., Zochbauer-Muller S., Shivakumar L., Fong K., Gao B., et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001, 93:691-699.
8. Endoh H., Yatabe Y., Shimizu S., Tajima K., Kuwano H., Takahashi T., et al. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. Int J Cancer 2003, 106:45-51.
9. Ito M., Ito G., Kondo M., Uchiyama M., Fukui T., Mori S., et al. Frequent inactivation of RASSF1A, BLU, and SEMA3B on 3p21.3 by promoter hypermethylation and allele loss in non-small cell lung cancer. Cancer Lett 2005, 225:131-139.
10. Wang J., Wang B., Chen X., Bi J. The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcinogenesis 2011, 32:411-416.
11. Jo H., Kim J.W., Kang G.H., Park N.H., Song Y.S., Kang S.B., et al. Association of promoter hypermethylation of the RASSF1A gene with prognostic parameters in endometrial cancer. Oncol Res 2006, 16:205-209.
12. Ma L., Zhang J.H., Liu F.R., Zhang X. Hypermethylation of promoter region of RASSF1A gene in ovarian malignant epithelial tumors. Zhonghua Zhong Liu Za Zhi 2005, 27:657-659.
13. Sugawara W., Haruta M., Sasaki F., Watanabe N., Tsunematsu Y., Kikuta A., et al. Promoter hypermethylation of the RASSF1A gene predicts the poor outcome of patients with hepatoblastoma. Pediatr Blood Cancer 2007, 49:240-249.
14. Tommasi S., Dammann R., Jin S.G., Zhang X.F., Avruch J., Pfeifer G.P. RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene 2002, 21:2713-2720.
15. Jacquemart I.C., Springs A.E., Chen W.Y. Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice. Int J Oncol 2009, 34:517-528.
16. Kudo T., Ikeda M., Nishikawa M., Yang Z., Ohno K., Nakagawa K., et al. The RASSF3 candidate tumor suppressor induces apoptosis and G1-S cell-cycle arrest via p53. Cancer Res 2012, 72:2901-2911.
17. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
18. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
19. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba I.I., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97:339-346.
20. Termen S., Tan E.J., Heldin C.H., Moustakas A. p53 regulates epithelial-mesenchymal transition induced by transforming growth factor beta. J Cell Physiol 2013, 228:801-813.
21. Thomson S., Petti F., Sujka-Kwok I., Mercado P., Bean J., Monaghan M., et al. A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis 2011, 28:137-155.
22. Cui T., Chen Y., Yang L., Knosel T., Huber O., Pacyna-Gengelbach M., et al. The p53 target gene desmocollin 3 acts as a novel tumor suppressor through inhibiting EGFR/ERK pathway in human lung cancer. Carcinogenesis 2012, 33:2326-2333.
23. Fukui T., Mori S., Yokoi K., Mitsudomi T. Significance of the number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol 2006, 1:120-125.
24. Shimizu K., Yoshida J., Nagai K., Nishimura M., Ishii G., Morishita Y., et al. Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005, 130:160-165.
25. Kanzaki R., Ikeda N., Okura E., Kitahara N., Shintani Y., Okimura A., et al. Surgical results and staging of non-small cell lung cancer with interlobar pleural invasion. Interact Cardiovasc Thorac Surg 2012, 14:739-742.
26. Heon S., Johnson B.E. Adjuvant chemotherapy for surgically resected non-small cell lung cancer. J Thorac Cardiovasc Surg 2012, 144:S39-S42.
27. Tsuboi M., Ohira T., Saji H., Miyajima K., Kajiwara N., Uchida O., et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Ann Thorac Cardiovasc Surg 2007, 13:73-77.
28. Hesson L.B., Wilson R., Morton D., Adams C., Walker M., Maher E.R., et al. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 2005, 24:3987-3994.
29. Schagdarsurengin U., Richter A.M., Hornung J., Lange C., Steinmann K., Dammann R.H. Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer 2010, 9:264.
30. Hesson L., Bieche I., Krex D., Criniere E., Hoang-Xuan K., Maher E.R., et al. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 2004, 23:2408-2419.